RJA
MNTA

Raymond James & Associates’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Raymond James & Associates’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,531
Closed -$849K – 3749
2020
Q2 		$849K Buy
25,531
+8,602
+51% +$274K ﹤0.01% 2268
2020
Q1 		$460K Buy
+16,929
New +$471K ﹤0.01% 2476
2019
Q4 		– Sell
-12,240
Closed -$159K – 3789
2019
Q3 		$159K Hold
12,240
– – ﹤0.01% 3325
2019
Q2 		$152K Sell
12,240
-1,000
-8% -$13.3K ﹤0.01% 3337
2019
Q1 		$192K Sell
13,240
-2,620
-17% -$33.5K ﹤0.01% 3255
2018
Q4 		$175K Sell
15,860
-3,656
-19% -$50.9K ﹤0.01% 3185
2018
Q3 		$513K Buy
19,516
+2,599
+15% +$70.3K ﹤0.01% 2691
2018
Q2 		$346K Buy
16,917
+8
+0% +$172 ﹤0.01% 2928
2018
Q1 		$307K Buy
16,909
+823
+5% +$13.7K ﹤0.01% 2865
2017
Q4 		$224K Buy
16,086
+115
+0.7% +$1.55K ﹤0.01% 2995
2017
Q3 		$295K Sell
15,971
-604
-4% -$10.1K ﹤0.01% 2808
2017
Q2 		$280K Sell
16,575
-145
-0.9% -$2.21K ﹤0.01% 2762
2017
Q1 		$223K Buy
16,720
+694
+4% +$10.9K ﹤0.01% 2869
2016
Q4 		$241K Sell
16,026
-43
-0.3% -$568 ﹤0.01% 2783
2016
Q3 		$188K Buy
+16,069
New +$189K ﹤0.01% 2868

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Raymond James & Associates's MNTA Position: Q3 2020 in Review

Raymond James & Associates sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2020, closing a stake of 25,531 shares — an estimated $849K sold.

Raymond James & Associates first reported a position in MNTA in Q3 2016 and held it in 15 quarters. The position peaked at $849K in Q2 2020. 211 funds tracked by Wall St. Rank hold MNTA as of Q3 2020.

  • Raymond James & Associates reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Raymond James & Associates sold 25,531 Momenta Pharmaceuticals, Inc. shares in Q3 2020, an estimated $849K.
  • Raymond James & Associates first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2016 and held it in 15 quarters.
  • Raymond James & Associates's Momenta Pharmaceuticals, Inc. position peaked at $849K in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2020.

Based on Raymond James & Associates's 13F filing for Q3 2020, filed 4 Nov 2020.